



- A pre-clinical stage biotech founded in 2022, based on the Comprehensive Amino Acid Transporter Platform.
- Developing APL1101 and APL1202 for Solid Tumors and Tumors located in deeper tissue, respectively

APL1101 – A Novel LAT1 Inhibitor, entirely locking the 3D structure and sustaining amino acid transport blockade

LAT1



In vivo tumor growth inhibition



- First/Best-In-Class LAT1 drug for Broader Tumor Type, since LAT1 is expressed in most of the tumor cells
- Inhibits Amino Acid Signaling and Protein Synthesis of tumor cells, resulting in the tumor growth inhibition
- Activates tumor immune microenvironment and turns “Cold” tumor to “Hot”
- GLP-tox study/IND-enabling planned to be completed in 2025, P1/2a trial for solid tumor planned to be started in 2026.

APL1202 – A disruptive drug for next generation Boron-Neutron Capture Therapy (BNCT) expanding the indication to the Advanced, deep-seated Solid Tumors



Courtesy of Prof. Ono, Osaka Medical and Pharmaceutical University, BNCT Center

	Current BNCT	NextGen BNCT with APL1202
Indication	Unresectable Recurrent H&N cancer	Advanced, Deep-seated Solid tumor (e.g. Pancreas)
ORR (CR+PR)	71.4%	around 80% (target)
T/N Ratio	3.5 : 1	30 : 1 (target)

Financing and Partnering

- \$1.8M Pre-Seed funding received to date, and
- Seeking \$5M Seeds funding for IND-enabling from VCs in Japan
- Also Seeking \$20M Series A round globally to conduct P1/2a trial starting in 2026
- Seeking opportunity for PharmaCo partnering